DRUG SURVIVAL ON FIRST TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS: COMPARISON ACROSS ETANERCEPT, ADALIMUMAB, GOLIMUMAB AND INFLIXIMAB

被引：0
|
作者：
Garcia-Porrua, C. [1 ]
Maceiras-Pan, F. [2 ]
Fernandez-Dominguez, L. [3 ]
Mosquera-Martinez, J. A. [4 ]
Correa-Rey, B. [5 ]
Pombo-Suarez, M. [6 ]
Pinto-Tasende, J. [7 ]
机构：
[1] HU Locus Augusti, Rheumatol, Lugo, Spain
[2] CHU Vigo, Rheumatol, Vigo, Spain
[3] CHU Ourense, Rheumatol, Ourernse, Spain
[4] CHU Pontevedra, Rheumatol, Pontevedra, Spain
[5] CHU Arquitecto Marcide Naval, Rheumatol, Ferrol, Spain
[6] CHU Santiago, Rheumatol, Santiago De Compostela, Spain
[7] INIBIC XXI A Coruna, Rheumatol, La Coruna, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.4951
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0333
引用
收藏
页码：1031 / 1031
页数：1
相关论文
共 50 条
  • [21] Comparison of healthcare costs in patients with psoriatic arthritis who received etanercept, etanercept plus methotrexate, infliximab, or infliximab plus MTX
    Dabbous, O.
    Rahman, M.
    Meissner, B.
    Thompson, H.
    Tang, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 258 - 258
  • [22] Golimumab Drug Utilization Patterns in Canada - Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
    Khalil, Hayssam
    Tahami, Amir
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S218 - S218
  • [23] Predictors for terminating therapy of etanercept and infliximab in psoriatic arthritis patients
    Kristensen, L. E.
    Nilsson, J.
    Jacobsson, L. T. H.
    Saxne, T.
    Compagno, M.
    Geborek, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 222 - 222
  • [24] Psoriatic arthritis patients doing better on infliximab than etanercept
    Smith, N.
    Gadsby, K.
    Deighton, C.
    RHEUMATOLOGY, 2007, 46 (04) : 721 - 722
  • [25] Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples
    Chun, Kelly
    Yang, Jane
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2098 - 2100
  • [26] RETENTION RATES OF ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB AS BIOTHERAPIES FOR RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, OR PSORIATIC ARTHRITIS PATIENTS IN DAILY PRACTICE IN AUVERGNE (FRANCE)
    Soubrier, M.
    Fan, A.
    Couderc, M.
    Malochet-Guinamand, S.
    Mathieu, S.
    Giraud, C.
    Tournadre, A.
    Dubost, J. -J.
    Pereira, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1756 - 1756
  • [27] Plasma Cytokines for the Prediction of the Effectiveness of TNFα Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis
    Karamova, Arfenya
    Znamenskaya, Ludmila
    Vorontsova, Anastasiia
    Obraztsova, Olga
    Nikonorov, Alexandr
    Nikonorova, Eugenia
    Deryabin, Dmitry
    Kubanov, Alexey
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (13)
  • [28] Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab
    María M. Katsicas
    Ricardo A. G. Russo
    Clinical Rheumatology, 2009, 28 : 985 - 988
  • [29] Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and infliximab
    Katsicas, M. M.
    Russo, R. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 551 - 552
  • [30] Infliximab, Etanercept, and Adalimumab switching in patients with rheumatoid arthritis in the CORRONA database
    Dabbous, O.
    Kremer, J.
    Rambharose, J.
    El Taha, M.
    Reed, G.
    Tang, B.
    Thomson, H.
    Domdey, A.
    Rahman, M.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 42 - 42
12345